CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc. Deutsche Boerse AG

Stocks

RV6

US1598641074

Biotechnology & Medical Research

Real-time Estimate Tradegate 02:45:30 2026-10-02 pm EDT			5-day change	1st Jan Change
256.85 ^EUR	-1.70%		-1.28%	+48.27%

Sep. 30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
Sep. 29	PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing	MT

All News

Mentions Relevance

Sep. 30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
Sep. 28	Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating	MT
Sep. 25	Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says	MT
Sep. 25	Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating	MT
Sep. 25	RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating	MT
Sep. 25	Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating	MT
Sep. 25	Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating	MT
Sep. 25	Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating	MT
Sep. 25	TD Cowen Adjusts PT on Charles River Laboratories International to $325 From $300, Maintains Buy Rating	MT
Sep. 25	Baird Adjusts PT on Charles River Laboratories International to $334 From $291, Keeps Outperform Rating	MT
Sep. 24	Charles River Laboratories International, Inc. - Analyst/Investor Day
Sep. 24	Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections	MT
Sep. 24	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS at Upper End of $11.15 - $11.45, vs. FactSet Est of $11.33	MT
Sep. 24	Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day	BU
Sep. 17	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
Sep. 17	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT
Sep. 17	Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines	BU
Sep. 16	Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says	MT
Sep. 15	Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
Sep. 14	Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
Sep. 11	Charles River Laboratories to Present at Morgan Stanley and Baird Conferences	BU
Sep. 11	Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating	MT
Sep. 09	Charles River Modernizes Endosafe(R) Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite	AQ
Sep. 08	Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite	CI
Sep. 08	Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite	BU